Passage Bio, Inc. filed a Current Report on Form 8-K on November 19, 2026, to provide financial information regarding its proposed merger with Remix Therapeutics, Inc. The filing confirms that Passage Bio’s stockholders approved the Amended and Restated Agreement and Plan of Merger on November 5, 2026. Under the terms of the agreement, Peregrine Merger Sub, Inc., a wholly owned subsidiary of Passage Bio, will merge with and into Remix, with Remix surviving as a wholly owned subsidiary. Following this, Remix will merge with and into Peregrine Merger Sub II, LLC, another wholly owned subsidiary of Passage Bio. Passage Bio intends to change its name to Remix Therapeutics, Inc. upon the completion of the mergers.

The filing includes unaudited condensed interim financial statements of Remix as of and for the nine months ended September 30, 2026, and 2025, as well as unaudited pro forma combined condensed financial information for Passage Bio, Remix, and the combined entity. The pro forma financials are presented as of and for the nine months ended September 30, 2026, and the year ended December 31, 2025. The company notes that these pro forma statements are based on certain assumptions and estimates and do not purport to reflect what actual results would have been had the mergers occurred on the assumed dates.

According to the unaudited condensed consolidated balance sheets for Remix Therapeutics, Inc. as of September 30, 2026, the company reported cash and cash equivalents of $29,264,000. Total assets were reported at $62,653,000. The unaudited condensed consolidated statements of operations for the nine months ended September 30, 2026, show collaboration revenue of $46,164,000 and a net loss of $14,438,000. The company reported a net loss attributable to common stockholders of $213,000 for the period.

The filing also details the company’s liquidity and capital resources. In connection with the proposed mergers, Remix entered into a subscription agreement for the purchase of approximately $70.0 million of common stock and/or pre-funded warrants. Additionally, the company issued approximately $30.0 million in aggregate principal amount of 2026 convertible promissory notes. These transactions resulted in aggregate gross proceeds of approximately $100.0 million to Remix. The company stated that these efforts are intended to provide sufficient capital to fund operations through the completion of the proposed mergers and for at least 12 months thereafter.